TScan Therapeutics Stock (NASDAQ:TCRX)

TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications. Beyond its oncology efforts, the company is also engaged in vaccine development for infectious agents, such as SARS-CoV-2. TScan has formed a strategic collaboration and licensing arrangement with Novartis Institutes for BioMedical Research, Inc., aimed at pinpointing novel cancer-specific antigens derived from the T cells of particular cancer patients. Founded in 2018, TScan Therapeutics, Inc. operates from its headquarters in Waltham, Massachusetts.